Hyperglycemia secondary to megestrol acetate for endometrial neoplasia

Gynecologic Oncology

Volumn 61, Issue 1, 1996, Pages 139-141

  Rose, Peter G ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL ACETATE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; ENDOMETRIUM TUMOR; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0029870152     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0112     Document Type: Article

References (20)

1. Bookman, J. V. Two pathogenic types of endometrial carcinoma, Gynecol. Oncol. 15, 10-17 (1983).
2. Wentz, W. B. Effect of a progestational agent on the endometrial hyperplasia and endometrial cancer, Obstet. Gynecol. 34, 370-375 (1964).
3. Gal, D., Edman, C. D., Vellios, F., and Forney, J. P. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia, Am. J. Obstet. Gynecol. 146, 316-322 (1983).
4. Bokhman, J. V., Chepick, O. F., Volkova, A. T., and Vishnevsky, A. S. Can primary endometrial carcinoma be treated without surgery and radiation therapy? Gynecol. Oncol. 20, 139-155 (1985).
5. Podratz, K. C., O'Brien, P. C., Malkasian, G. D., Decker, D. G., Jefferies, J. A., and Edmonson, J. H. Effects of progestational agents in treatment of endometrial carcinoma, Obstet. Gynecol. 66, 106-110 (1985).
6. Moore, T. D., Philips, P. H., Nerenstone, S. R., and Cheson, B. D. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions, J. Clin. Oncol. 9, 1071-1088 (1991).
7. DiSaia, P. J., and Creasman, W. T. Clinical gynecologic oncology, Mosby, St. Louis, 4th ed., pp. 186 (1993).
8. Cohen, C. J. Advanced (FIGO stages III and IV) and recurrent carcinoma of the endometrium, in Gynecologic Oncology (M. Coppleson, J. M. Monaghan, C. P. Morrow, and M. H. N. Tattersal, Eds.), Churchill Livingstone, Edinburgh, 2nd ed., pp. 796-797 (1992).
9. Gusberg, S. B. Treatment of cancer of the endometrium, in Female Genital Cancer (S. B. Gusberg, H. M. Shingleton, and G. Deppe, Eds.), Churchill Livingstone, New York, pp. 374 (1988).
10. Garrison, R. N., Cryer, H. M., Howard, D. A., and Polk, H. C. Classification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann. Surg. 199, 648-654 (1984).
11. Trope, C., and Lindahl, B. Premalignant lesions of the endometrium: Clinical features and management, in Gynecologic oncology (M. Coppleson, J. M. Monaghan, C. P. Morrow, and M. H. N. Tattersal, Eds.), Churchill Livingstone, Edinburgh, 2nd ed., pp. 747-751 (1992).
12. Kohorn, E. I. Gestagens and endometrial carcinoma, Gynecol. Oncol. 4, 398-411 (1976).
13. Ferenczy, A., and Gelfand, M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am. J. Obstet. Gynecol. 160, 126-131 (1989).
14. Physicians' desk reference, Medical Economics Co., Montvale, NJ, pp. 669-670 (1995).
15. Loprinzi, C. L., Ellison, N. M., Schaid, D. J., et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia, J. Natl. Cancer Inst. 82, 1127-1132 (1990).
16. Feliu, J., Gonzales-Baron, M., Berrocal, A., et al. Usefulness of megestrol acetate in cancer cachexia and anorexia: A placebo-controlled study, Am. J. Clin. Oncol. 15, 436-440 (1992).
17. Henry, K., Rathgaber, S., Sullivan, C., and McCabe, K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia, Ann. Intern. Med. 116, 53-54 (1992).
18. Bornemann, M., and Johnson, A. C. Letter, N. Engl. J. Med. 328, 890 (1993).
19. Grinspoon, S. K., and Bilezekian, J. P. HIV disease and the endocrine system, N. Engl. J. Med. 327, 1360-1365 (1992).
20. Aisner, J., Tchekmedyian, N. S., Moody, M., and Tait, N. High-dose megestrol acetate for the treatment of advanced breast cancer: Dose and toxicities, Semin. Hematol. 24, 48-55 (1987).